Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Receivables (2020 - 2025)

Historic Receivables for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $27.7 million.

  • Burning Rock Biotech's Receivables rose 534.39% to $27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year increase of 534.39%. This contributed to the annual value of $22.7 million for FY2024, which is 783.98% up from last year.
  • Latest data reveals that Burning Rock Biotech reported Receivables of $27.7 million as of Q3 2025, which was up 534.39% from $28.6 million recorded in Q2 2025.
  • Burning Rock Biotech's 5-year Receivables high stood at $28.6 million for Q2 2025, and its period low was $4.5 million during Q2 2022.
  • Over the past 5 years, Burning Rock Biotech's median Receivables value was $23.9 million (recorded in 2024), while the average stood at $22.1 million.
  • In the last 5 years, Burning Rock Biotech's Receivables crashed by 6278.61% in 2022 and then soared by 51891.65% in 2023.
  • Burning Rock Biotech's Receivables (Quarter) stood at $27.3 million in 2021, then rose by 3.49% to $28.2 million in 2022, then decreased by 25.32% to $21.1 million in 2023, then grew by 7.84% to $22.7 million in 2024, then rose by 21.71% to $27.7 million in 2025.
  • Its Receivables was $27.7 million in Q3 2025, compared to $28.6 million in Q2 2025 and $24.3 million in Q1 2025.